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President Brewster, Dr. Cole, Dr. Berliner, ladies and gentlemen:
As Chairman of the President's Cancer Panel, I am delighted to be in New Haven
for the groundbreaking ceremonies for the Comprehensive Cancer Center at Yale.
This great university has been preeminent in biomedical science, and the establish-
ment ofa Comprehensive Cancer Center will, I am sure, enhance Yale's contribution
both to the fundamental understanding of cancer and to the quality ofclinical care
for the cancer patient.
These are very interesting days for those ofus responsible for the National Cancer
Program. While the cancer program has had the strong support ofthe Congress, the
administration, the public, and a large segment ofthe scientific community, criticisms
are still coming in from many quarters and these criticisms need careful listening to
and even more careful sorting out. There are hard things being said, and we need to
think our way carefully through the answers.
This morning I would like to deal with several of the important questions that
continue to arise and see if we can, to some extent at least, separate myth and
misconceptions from valid criticisms.
The two most persistent questions about the cancer program deal with opposite
sides of the same issue. On the one hand it is said that there is not a sufficient
recognition in the cancer program ofthe importance offundamental basic research.
The opposite and equally vehement criticism is that we are spending too much on
fundamental basic research and not enough on applied and clinical research oriented
toward a more immediate payoff. Other criticisms of the program include the
suggestion that those in charge of the program are under the mistaken impression
that techniques ofbusiness management can be used to unravel the profound mystery
of biology; that an attempt is being made to target research that cannot be targeted;
that we have become shackled by our own efforts at planning in areas where planning
is impossible; that our insistence on targeting has resulted in an enhanced use of
contracts at the expense of grants, and that contracts mean less effective research;
that our preoccupation with centers is causing us to fund second-rate research at
places called centers while first-rate research applications go begging in our tradition-
ally excellent educational institutions; that control, demonstration and service ex-
penditures are siphoning offthe funds which should be used for research; that there is
a lack of appreciation of the necessity for training the manpower that is needed to
provide for the continuity of excellence that good research demands; and that the
cancer program is raising false hopes and false expectations that will result in
disillusionment and ultimate abandonment of the program to the detriment of all
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All rights of reproduction in any form reserved.science. These are the most frequently voiced complaints. There are others, but the
ones I have mentioned provide more than a full plate for this morning's allocation of
time.
First, is the cancer program supporting enough basic research? To put the answer
to that question in context, let us take a brief look at a bit ofhistory. In 1970, when
the Senate of the United States appointed a Senate panel to make recommendations
with respect to cancer research, biomedical research in general and cancer research in
particular were on the back burner. The budget ofthe NCI was $180 million. In 1971,
as a result of the discussions which the Senate panel stimulated in the Congress, the
NCI budget was increased to $228 million. In 1972, the first year after the passage of
the National Cancer Act, the budget was $378 million. In 1973 it was $432 million. In
1974, $589 million. In 1975, $691 million. In 1976, $762 million, and this year's
budget looks like $815 million. As a result of these increases, we have been able to
give this country programs in both basic biomedical research and clinically-oriented
research in cancer that are unprecedented, both in their scope and their excellence.
While the other institutes of the NIH have not had increases comparable to cancer,
the total NIH budget for biomedical research is two and one half billion dollars in
1977 compared to 1 billion, 143 million dollars in 1970.
In 1976, 52% of the NCI budget, or $396 million, was spent on basic research. This
compares with less than $100 million in 1970. Throughout the past five years, the
National Cancer Program has consistently devoted about one-half ofthe substantial
budget increases to the support ofbasic research. Moreover, a large portion ofthat is
investigator-initiated, peer-reviewed, grant-supported, basic research. For example,
of the $396 million devoted to basic research in this year, $152 million represents
traditional research grants, $58 million represents the basic research portion of
program project grants, $30 million represents support of basic research in the
excellent Intramural Program on the NIH campus, $30 million is for construction
and fellowship grants in support of basic research, and $79 million represents
research contracts in areas, such as virology, which were already being supported by
the contract mechanism prior to the passage ofthe National Cancer Act of 1971, and
which, with strengthened peer review, we have continued to support by contract
rather than disrupt good ongoing programs. These amounts are spent in support of
fundamental research to expand our knowledge at the most basic levels. So when my
friend, Arthur Kornberg, says, "We don't know enough about biology to do a proper
job in spending huge amounts of money successfully on cancer," it seems to me that
this loses sight of the fact that a very substantial amount of the money provided for
cancer research goes to the support ofexcellent basic biological research in the very
areas of ignorance to which Dr. Kornberg refers.
During a recent hearing of the Senate Health Subcommittee, I was asked whether
we should be supporting so much basic research under the cancer program. The
question was, "Can we afford so much basic research or should we devote our funds
to activities where the probable payoff is more immediate and more apparent?" My
answer is that we cannot afford not to support basic research. Without it, there will
be no payoffs. Basic research is still the lifeline of medicine. It is essential in order to
provide the science base upon which to build improved technologies for prevention,
diagnosis, and treatment of cancer. What we need at the end of the line, and simply
must have if cancer is to be eliminated from the roster ofmajor human diseases, is an
understanding of the underlying processes of cancer at a far more profound and
sophisticated level than we possess today. For we are, in truth, profoundly ignorant
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about the real nature of cancer. We do not really understand what happens. We
cannot fully explain the processes, although there are now attractive clues all over the
place. Viruses may be centrally involved, in some cancers at least they probably are,
and therefore virology is an important part of the effort. The basic processes ofcell
differentiation and membrane structure and physiology are surely involved, and we
are moving in those areas. Carcinogenesis, cellular genetics, molecular biology,
immunological recognition systems, the regulators of growth and differentiation,
perhaps even influences of the nervous system-all of these represent fields for
inquiry, and none of us can really predict at this stage of our ignorance where the
most crucial bits of information now lie hidden away from us. We are confronted by
one of the most complex mysteries in all of nature. There are no books to follow for
instruction. Committees cannot provide us with the questions we need, much less the
answers. We must explore every lead that looks like a good lead, watching for
suggestions. For work of this kind we are totally dependent on the flexibility of
human imagination, above all the imagination of our youngest and brightest investi-
gators.
We are looking for new ground, but we have come far enough along in the
biological revolution to know, for an absolute certainty, that the problem ofcancer is
an approachable and soluble biological problem, even though none ofus can predict
when or at what cost. This is the reason that expenditures for basic research under the
cancer program since 1972 have totaled well over $1 billion and a large fraction of
this is investigator-initiated, peer-reviewed, grant-supported, basic research being
done under increasingly rigorous standards of peer review for excellence.
We must continue the support of fundamental basic research, and no one should
assume that good basic research cannot be supported by a categorical institute.
Whether this basic research involves research directed at disease mechanisms, cate-
gorical in the sense that investigators willbe driven by their own interest in the puzzle
of one disease or another, or whether it is noncategorical, pure, undifferentiated
biomedical research of the kind that has taken us deep into the biological revolution,
we must encourage and support this type of research. It is the excellence of the
research that matters, not whether it is supported by the Cancer Institute or the
Institute of General Medical Sciences. I think some scientists assume that if basic
research is supported by the Cancer Institute, it is somehow targeted or directed.
That is not so.
One thing that worries me is the developing notion that there is good basic
biomedical research that is relevant and there is good basic biomedical research that
is not relevant, and that scientists or administrators should be able to tell the
difference in advance. I doubt that relevance in basic biomedical science is identifi-
able in advance. The individual questions are much too small. It is the total of the
science base that becomes relevant, and any building block that elucidates cell
structure or mechanisms is relevant, although it may not seem so when described
separately in advance. We must not allow this notion or any other to erode our
support of the best basic science.
Simultaneously with the expansion of our knowledge through the support of
fundamental research, we must also make the best effort of which we are capable
today in the areas of prevention, diagnosis and treatment of cancer. This means the
support ofapplied research where an adequate science base exists and the support of
clinical research for the development, application, and trial of the best technologies
of which we are capable. In 1976, $241 million was obligated under the cancer
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support of research in clinical treatment. While we have not had spectacular break-
throughs in cancer comparable to the antibiotics in infectious diseases or the polio
vaccine there is no question that the cancer patient has a better chance today in the
hands of good cancer doctors than has been true at any time in the past. Not only are
we doing better all the time with acute lymphocytic leukemia, osteogenic sarcoma,
and a number of other tumors in children, Hodgkin's disease and other lymphomas,
but a new era has begun in the use of combination therapy in treating the more
common tumors. Postoperative or postradiation chemotherapy appears to be effec-
tive in a large number of cases to avoid metastasis and recurrence where surgery or
radiation or both are used to eliminate the primary tumor. In addition, it has now
become apparent that tumors are antigenic and immunotherapy therefore will almost
certainly become an important tool in treatment, particularly in the postoperative
periods when low volumes of tumor exist.
It is quite possible then that even with ourexisting tools we may be able to improve
significantly the survival of patients today. In those cases where tumors are resec-
table, there has been a tremendous increase in the past three or four years in the
emphasis upon the use ofchemotherapy and immunotherapy postoperatively to treat
those patients with detectable or nondetectable micrometastases. Early results with
these techniques are veryencouraging and it now appears likely that cure rates will be
materially increased for such common cancers as breast and colon cancer over those
achieved in the past by surgery alone.
These recent developments represent a drastic alteration in the way medicine is
practiced in this country. Utilization of these advances in cancer treatment often
requires the melding of the talents of several specialties, the surgeon or radiation
therapist, the medical or pediatric oncologist, and the researcher, and such a joint
effort has not been and is not today common medical practice. It must become more
common in cancer therapy, so long as our basic knowledge is at present levels, and
this is an area where I hope we can look to the Comprehensive Cancer Centers such
as the one here at Yale to lead the way.
Under the Cancer Control Program we are mandated by the Congress to extend
our clinical research to demonstration programs in those areas where beneficial
technologies exist but where their acceptance and utilization is not widespread. This
is an area that troubles a great many scientists because they are concerned that the
entry of the NCI into the service area, even to this extent, willultimately result in the
diminishing of its resources for research. Fortunately, the Congress has to date been
willing to budget the control activities separately, and I see no indication ofachange
in this policy. So long as this is true, the NCI should be able to expend the control
dollars usefully without diminishing its research capability.
As for targeting, I wish that I could make clear once and for all the fact that those
who manage the national cancer effort are not obsessed with the idea of targeting.
There is some applied research that can and should be targeted because the science
base exists, and in those cases, with the advice of the best scientists available, a
targeted effort is made. However, we are as aware as anyone anywhere of the
limitations of targeted research, and we are not attempting to target the basic
research that will give us the understanding of the origins and nature of cancer.
Similarly, with respect to the issue of contracts vs. grants, we have been substantially
diminishing the percentage of contract support and increasing grant support in the
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area of basic science, and we intend to continue to do so. One of the problems of
communications has been that our budgets often lump all contracts together, and this
figure is sometimes taken by members of the scientific community to represent
contract research. In fact, over half of the contract expenditures are for necessary
supplies and services which can only be obtained through the contract mechanism.
The contract mechanism is used for the support of basic research today primarily in
those areas where it was in use prior to the passage ofthe National Cancer Act, and in
these limited areas its use with strengthened peer-review has been continued in order
not to impede strong ongoing programs. However, the present management of the
NCI has been de-emphasizing the contract mechanism in the support of basic
research and will continue to do so.
This brings me to the National Cancer Plan which has been the subject ofso much
criticism from so many scientists. When Dr. James Watson was reported last year as
having said at M.I.T. that the National Cancer Program was a "sham," he was, in
fact, talking about the National Cancer Plan. He made this somewhat clearer in a
letter ofapology than he did in his speech, but there is no question that he was talking
about the plan and not the program. I suspect that if we took a vote, most scientists
would be happier if there were no cancer plan-if there had never been a plan. It
seems to imply to a lot of people that somebody in a position ofauthority thinks that
the problems of cancer can be dealt with in the same manner as the problems of
building an atom bomb or landing a spacecraft on the moon. I assure you this is not
true. The plan is not designed for the purpose oftelling us how to run the program.
The plan was an attempt by the scientific community, by those responsible for doing
the science, to indicate those areas which, at the present time, seem to offer the
greatest promise. Like most plans, its principal value may well be in the communica-
tions which take place during the planning process. It is also a useful vehicle for
assessing the program on a continuing basis, and presenting the program to OMB
and the Congress. However, it does not put the program in any sort of straitjacket
nor does it put blinders on those who are administering the program. The programis,
in fact, what goes on at several hundred educational and research institutions, plus
the intramural work at the NCI. This is determined almost entirely by the best peer-
review available in the scientific community. So, in the last analysis, peer-review, not
the plan, determines the cancer program.
Those of you who are engaged in this work at your own universities know that the
plan is not determining what science you do or how you do it. I have never felt that
worries about the plan were particularly well-founded. Of course there is a large
element of unplanned, untargeted, undirected, investigator-initiated science required
in this undertaking, but no one thinks differently and there is nothing in the plan to
cause them to think differently. The program is designed to provide an open system
with fair and even peer-review and an environment optimal for discovery. We need
brilliance, hard work, serendipity, and a large measure of good luck. I hope we are
doing nothing to block ourselves off from any of these.
Another frequently heard charge, and one also recentlyrepeated by Dr. Watson at
M.I.T. is that our centers' support represents the support of inferior research and
thus deprives institutions of greater excellence of that support. This allegation does
not withstand examination. In supporting the 17 comprehensive centers that have
thus far been recognized, we are not only helping to bring better clinical care to a
greater number of our citizens, but we are also supporting some ofthe best research
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institutions that exist in this country. I think no one would question that the
fundamental research done at this great university where we are gathered today, at
Wisconsin, Sloan-Kettering, University of Chicago, Duke, the Institute for Cancer
Research, Roswell Park, M.D. Anderson, Johns Hopkins, the Farber Institute at
Harvard, the Fred Hutchinson Cancer Research Center in Seattle, the University of
Alabama, Mayo, Southern California, Colorado, and Miami compares favorably
with the best biomedical research anywhere. Moreover, by historic happenstance, we
support under our centers' program research not only at the great institutions which I
have mentioned as recognized Comprehensive Cancer Centers, but also at many
other institutions that have been called specialized centers because they receive
program project grants, including Stanford, the University of California, Indiana,
Harvard, M.I.T., the University of Minnesota, Albert Einstein, Mount Sinai, and
some fifty other fine institutions too numerous to mention, but including, ironically
Cold Spring Harbor Laboratory, where Dr. Watson's support has gone from
$435,000 in 1970 to $1,962,665 in 1976 under the NCI Centers' Program. So I say to
Dr. Watson and those like him who question the excellence of the research supported
under the centers' program that peer-review is alive and well in the centers' program
just as it is in other programs of the National Cancer Institute.
There is a legitimate worry about the Comprehensive Cancer Centers which relates
to future funding in the event of the recognition of too many such centers. Compre-
hensive Cancer Centers must compete on the merits with all other institutions for the
cancer research dollar. Therefore, if too many centers are recognized and we have
centers which cannot compete on the merits, we will then be in a position of having
recognized centers which we are unable to support. The fear is that, under those
circumstances, political pressures would be brought to bear which would force the
support of the comprehensive centers at the expense of other institutions capable of
better cancer research. The answer to this perceived future problem is strictly to limit
the recognition of the comprehensive centers and to recognize them only at institu-
tions that are established academic and scientific leaders clearly capable ofcompeting
on the merits.
The most serious mistake we have made in the support of our biomedical research
during the short period that I have been actively associated with this enterprise was
the discontinuance byOMB of the biomedical fellowship and training programs. It is
absolutely essential to our success in the cancer program and in biomedical research
generally that we bring a portion of our brightest young people into these programs,
and fellowships and training grants have proved to be the most effective and most
economical ways ofdoing that. These are among the best dollars we spend in terms of
value received.
Fortunately, one way or another the NCI has been able to keep its training
programs going at about the same dollar level as existed before theOMB action.
However, the training programs of other parts of the NIH, particularly the predoc-
toral programs of GMS, have been adversely affected, and that ultimately affects the
cancer program as surely as if these programs were in the NCI.
One of the worst aspects of the training picture during the past few years under
both the Weinberger Program and the National Research Training Act has been the
on again-off again uncertainty that comes with defining new programs, producing
new regulations, not having funds in certain periods, having funds in other periods,
and putting the whole research establishment in the hurry-up-and-wait, now-you-
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have-it-now-you-don't posture. However, we are supporting training substantially,
and I hope we can get a uniform understanding and a uniform program that can go
on year after year without the turbulence that has characterized the past several
years. This has been very distressing, I know, from the standpoint ofthe institutions,
and it has made for less efficient expenditure of the federal dollars in this field.
Before concluding, I would like to say a few words about the biomedical research
budget, because there is no question that the combined problems of inflation and
recession and the economic difficulties which confront us have created great pressure
for the reduction of federal expenditures on biomedical research. This is one ofthe
few areas that can be reduced and therefore it is a prime target. However, it is my
opinion, and has been my advice to the President and to the Congress that it would
be a serious mistake to cut these programs in such a way as to lose the momentum
that has been established. I think we must continue our federal support.
Unfortunately, in a free enterprise system, basic biomedical research cannot be
carried forward on the scale that is required without federal support. Profit incentives
are not there to support adequate basic research in this area, and philanthropic
institutions, while providing the bulk of the facilities and personnel needed for this
enterprise, must have government help in order to stimulate their activities and to
sustain them at the level which the public interest requires. It is this mix of public
support and private sector initiative that has made our biomedical researchestablish-
ment the envy of the world.
The cost of medical care is such an enormous and increasing expense for our
people and, therefore, for the government, that we cannot afford to starve the
research efforts which will provide us the knowledge we need to avoid the crushing
burdens of medical care. If it were not for the results of past biomedical research, we
would still be saddled today with the horrendous costs and burdens oftuberculosis,
polio, and all ofthe infectious diseases which through the products of research have
been virtually eliminated from our medical picture. We must continue our research
until cancer, heart disease, stroke, arthritis, multiple sclerosis, diabetes, and other
diseases that agonize our people and fill our hospitals have been added, or largely
added, to that list.
If any well-run business were spending $130 billion per year on medical care, it
would be spending at least 5% of that amount on research to reduce those costs.
While we cannot go to that level under today's circumstances, sound business
judgment requires that we not cut back on the present effort.
Finally, the federal expenditures in biomedical research are leverage dollars.
Hundreds of millions ofdollars ofinstitutional facilities built by our universities and
other philanthropic institutions, and thousands of people whose salaries are paid by
these institutions, are mobilized in the cause of biomedical research by the relatively
few federal dollars that are spent in stimulating this activity. However, stop the flow
of federal dollars under today's circumstances, and these essential activities willgrind
virtually to a standstill. This we must not do.
In conclusion, all of you in the scientific and medical community, and all of us
connected with the program must continue to explain at every opportunity to the
American people and to the Congress that the cancer program is a vast undertaking
which will require long-term support and great patience. We are still far away from
being able to put either a date or a price tag on the ultimate conquest of cancer. We
are making progress in our understanding of this disease, and there is no question
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that the benefits of our research are increasingly available to the American people in
the form of better treatment as time goes by. But it is a long road that will require
patience and constancy on the part of the Congress, the administration, and the
public. In fact, at this stage ofour progress, it is true in a very real sense that "the goal
is the course we travel together, and the end is only the beginning."
And so today, as we break ground for a great new Comprehensive Cancer Center
here at Yale, we reaffirm once again our mission,
To sail beyond the sunset, and the baths of all the western stars . . .
To strive, to seek, to find, and not to yield.
Thank you.
Benno C. Schmidt
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